vaccin
consid
one
greatest
advanc
modern
medicin
global
burden
numer
infecti
diseas
significantli
reduc
case
effect
erad
deploy
specif
vaccin
howev
effort
develop
effect
new
vaccin
infecti
pathogen
influenza
human
immunodefici
viru
hiv
dengu
viru
denv
chikungunya
viru
chikv
ebola
viru
zika
viru
zikv
proven
challeng
zika
viru
mosquitovector
flaviviru
respons
period
outbreak
diseas
africa
southeast
asia
pacif
island
date
back
year
period
zikv
infect
subclin
infect
individu
result
mild
case
fever
arthralgia
rash
other
concern
zikv
chang
past
two
year
howev
outbreak
brazil
central
american
countri
caribbean
island
reveal
novel
aspect
infect
includ
vertic
sexual
transmiss
mode
case
report
show
dramat
neurolog
patholog
includ
microcephali
neurodevelopment
problem
babi
born
zikv
infect
mother
well
increas
risk
guillainbarr
syndrom
adult
find
prompt
world
health
organ
declar
zikv
public
health
emerg
result
expand
effort
develop
zikv
vaccin
immunotherapeut
sever
zikv
vaccin
candid
immunogen
effect
block
zikv
infect
anim
model
sinc
develop
evalu
clinic
addit
therapeut
investig
includ
antizikv
monoclon
antibodi
mab
shown
neutral
infect
vitro
well
protect
morbid
mous
model
zikv
infect
review
summar
current
understand
zikv
biolog
describ
effort
rapidli
develop
vaccin
zikv
nearli
year
discoveri
zika
viru
zikv
larg
ignor
world
scientif
medic
commun
believ
caus
mild
selflimit
symptom
minor
infect
individu
indiffer
turn
grave
concern
zikv
outbreak
brazil
reveal
insidi
new
sign
symptom
infect
well
new
mode
transmiss
viru
specif
transmiss
sexual
contact
among
previous
unappreci
symptom
appear
sever
microcephali
congenit
defect
babi
born
zikvinfect
pregnant
women
particularli
women
infect
earli
pregnanc
appear
new
sequela
combin
zikv
rapid
global
spread
prompt
world
health
organ
declar
zikv
infect
public
health
emerg
earli
unleash
concert
effort
scientist
health
profession
understand
pathogenesi
spread
treatment
option
emerg
infecti
agent
lift
zika
declar
end
scientif
research
stimul
led
deeper
understand
zikv
pathogenesi
develop
vaccin
candid
combat
zikv
infect
diseas
zika
viru
member
flaviviru
genu
flavivirida
famili
group
positivesens
singlestrand
rna
virus
among
genu
sever
clinic
import
virus
includ
yellow
fever
viru
yfv
japanes
enceph
viru
jev
tickborn
enceph
viru
tbev
west
nile
viru
wnv
four
subtyp
dengu
viru
flavivirus
transmit
vertebr
insect
vector
thu
also
classifi
arthropodborn
virus
arbovirus
genet
zikv
nucleotid
ident
spondweni
viru
nucleotid
ident
jev
wnv
four
denv
serotyp
immunolog
crossreact
respons
observ
sever
virus
play
role
earli
studi
character
famili
infect
importantli
efficaci
vaccin
previous
develop
yfv
jev
suggest
flavivirus
vaccin
tractabl
effort
develop
vaccin
flavivirus
encount
uniqu
setback
includ
difficulti
induc
broad
neutral
antibodi
vari
hepat
c
viru
recent
observ
live
attenu
yellow
fever
recombin
tetraval
denv
vaccin
associ
sever
infect
specif
seroneg
individu
group
children
follow
vaccin
review
discuss
effort
develop
synthet
dnabas
vaccin
respond
outbreak
zikv
diseas
began
brazil
start
effort
laboratori
experiment
system
reagent
anim
model
could
employ
zikv
vaccin
develop
furthermor
pauciti
studi
biolog
immunolog
zikv
provid
guidanc
effect
combat
spread
evalu
vaccin
develop
relat
yfv
denv
strongli
suggest
antibodi
envelop
e
antigen
zikv
analog
might
import
immun
correl
protect
zikv
vaccin
despit
obstacl
group
accept
challeng
develop
effect
zikv
vaccin
abl
develop
candid
advanc
phase
clinic
trial
seven
month
declar
histor
record
phylogenet
analys
zikv
indic
viru
origin
near
uganda
spread
global
eastward
africa
tropic
zika
viru
first
isol
sentinel
monkey
develop
fever
studi
arbovirus
conduct
zika
forest
uganda
human
serolog
evid
zikvinfect
report
east
africa
macnamara
report
three
person
febril
ill
occur
outbreak
yellow
fever
nigeria
manifest
zika
viru
seroconvers
howev
first
document
isol
zikv
human
part
challeng
studi
human
research
manifest
mild
viral
infect
character
headach
malais
total
bodi
rash
first
report
zikv
outsid
africa
occur
malaysia
next
decad
case
zikv
infect
report
throughout
southeast
asia
outsid
africa
asia
first
report
outbreak
zikv
infect
occur
yap
island
western
pacif
next
year
eastward
progress
continu
outbreak
zikv
infect
report
multipl
island
throughout
pacif
ocean
one
largest
outbreak
occur
french
polynesia
report
case
outbreak
first
evid
neurolog
symptom
follow
zikv
infect
note
dramat
uptick
guillainbarr
e
syndrom
case
island
outbreak
start
compar
previou
year
analys
suggest
multipl
introduct
zikv
western
hemispher
begin
late
earli
epicent
infest
northeast
brazil
end
autochthon
zikv
transmiss
report
tropic
countri
western
hemispher
caribbean
well
far
southern
region
continent
unit
state
zika
viru
circul
enzoot
sylvat
cycl
well
urban
cycl
mosquito
speci
aed
genu
serv
primari
vector
mani
arbor
aed
speci
includ
aed
africanu
carri
zikv
thu
like
major
mediat
sylvat
transmiss
urban
transmiss
primarili
mediat
aed
aegypti
mosquito
although
aed
albopictu
aed
hensilli
urban
mosquito
may
also
play
role
addit
infect
acquir
blood
meal
infect
host
anim
zikv
pass
vertic
mosquito
via
transovari
transmiss
viral
genom
serum
antibodi
target
zikv
found
multipl
nonhuman
primat
nhp
speci
make
like
reservoir
serosurvey
limit
genet
test
indic
divers
organ
includ
bat
sheep
goat
cattl
water
buffalo
bird
may
also
suscept
infect
model
studi
show
potenti
nhp
serv
zikv
reservoir
appar
increas
virul
transmiss
zikv
western
hemispher
outbreak
suggest
acquir
mutat
sever
analys
divers
global
zikv
isol
found
high
degre
similar
contemporari
earli
strain
zikv
sequenc
analys
zikv
show
segreg
two
lineag
african
asian
roughli
ident
genet
level
despit
diverg
zikv
circul
singl
serotyp
zikv
strain
respons
brazil
western
hemispher
outbreak
part
asian
lineag
ongo
investig
sequenc
contemporari
zikv
contribut
zikv
virul
transmiss
one
studi
note
amino
acid
aa
border
glycosyl
site
asn
zikv
envelop
protein
present
flavivirus
differ
zikv
strain
suggest
region
may
play
role
viru
transmiss
andor
virul
liu
et
al
identifi
spontan
alaninetovalin
amino
acid
substitut
protein
contemporari
zikv
strain
increas
infect
aegypti
mosquito
analog
chang
genet
sequenc
alphaviru
chikungunya
aid
abil
infect
albopictu
mosquito
contribut
outbreak
diseas
indian
ocean
nation
yuan
colleagu
identifi
serin
asparagin
mutat
appear
zikv
strain
around
prior
outbreak
french
polynesia
mutat
stabli
maintain
zikv
isol
vitro
experi
suggest
presenc
caus
increas
zikv
infect
human
mous
neural
progenitor
cell
npc
well
microcephali
fetal
demis
mous
model
typic
zika
virion
roughli
spheric
shape
consist
capsid
c
proteinencapsul
genom
surround
phospholipid
bilay
embed
envelop
e
membran
protein
zikv
genom
kb
positivesens
singlestrand
rna
encod
three
structur
protein
c
premembranemembran
prm
e
seven
nonstructur
ns
protein
virion
assembl
bud
endoplasm
reticulum
er
use
poorli
defin
process
nm
diamet
noninfecti
immatur
particl
contain
roughli
trimer
prme
heterodim
immatur
particl
spiki
appear
cryoelectron
microscopi
cryoem
imag
due
e
protein
adopt
bent
conform
fusion
peptid
expos
shield
fulllength
prm
protein
prevent
prematur
fusion
viral
cellular
membran
immatur
particl
transit
secretori
pathway
resid
furin
proteas
tran
golgi
network
cleav
prm
protein
leav
protein
embed
bilay
solubl
pre
peptid
remain
virion
disassoci
virion
releas
function
protein
matur
virion
unknown
prm
cleavag
oppos
headtotail
e
protein
dimer
flatten
along
surfac
herringbonelik
pattern
result
nm
diamet
matur
infecti
particl
extern
portion
e
protein
contain
three
distinct
domain
di
dii
diii
link
viral
membran
via
helic
stem
region
connect
two
transmembran
domain
fig
zika
virion
enter
cell
via
endocytosi
low
ph
environ
earli
late
endosom
trigger
conform
chang
e
protein
conform
chang
expos
fusion
peptid
mediat
merg
viru
cell
membran
specif
cellular
protein
involv
zikvflaviviru
entri
remain
poorli
defin
varieti
nonspecif
protein
includ
ctype
lectin
specif
dcsign
dcsignr
well
phosphatidylserin
receptor
tim
celltransmembran
immunoglobulin
mucin
tam
axl
mer
protein
famili
may
play
role
viru
attach
andor
entri
studi
indic
axl
bind
zikv
effici
flavivirus
may
central
zikv
entri
fetal
endotheli
cell
well
neuron
cell
howev
experi
mice
indic
axl
requir
infect
suggest
role
molecul
viral
entri
ineffici
flaviviru
assembl
matur
lead
releas
mixtur
immatur
virion
matur
virus
partial
matur
virion
cell
wholli
immatur
particl
noninfecti
could
relev
immunolog
elicit
antibodi
respons
e
protein
epitop
hidden
partial
expos
matur
virion
partial
matur
virus
like
infecti
thu
contribut
along
matur
virus
pathogenesi
addit
full
virion
subvir
particl
svp
contain
prm
e
protein
without
capsid
viral
genom
also
produc
byproduct
flaviviru
assembl
svp
noninfecti
immunogen
transit
secretori
system
caus
e
protein
svp
adopt
similar
conform
packag
seen
full
virion
cellular
express
flaviviru
prm
e
protein
drive
svp
format
other
exploit
concept
develop
test
novel
zika
immunogen
despit
recent
observ
new
sever
sign
zikv
infect
popul
major
peopl
infect
like
experi
subclin
mild
symptom
zikv
clinic
diseas
typic
present
symptom
appear
day
postinfect
gener
includ
rash
mild
fever
arthralgia
conjunct
viru
isol
patient
blood
approxim
seven
day
clinic
present
urin
day
viral
rna
detect
semen
six
month
follow
infect
symptom
zikv
infect
resolv
two
week
post
infect
antibodi
zikv
appear
averag
nine
day
postinfect
believ
provid
longterm
perhap
lifelong
protect
futur
infect
guillainbarr
syndrom
gb
ill
character
progress
loss
motor
function
may
result
requir
need
mechan
respiratori
support
gb
first
appreci
complic
zikv
infect
outbreak
french
polynesia
retrospect
analysi
outbreak
found
attack
rate
gb
develop
case
per
zikv
infect
contrast
campylobact
jejuni
associ
gb
antigangliosid
antibodi
univers
detect
detect
autoantibodi
found
approxim
zikvinfect
individu
suggest
potenti
altern
etiolog
although
report
zikv
detect
nerv
tissu
gb
patient
studi
show
zikv
readili
infect
neuron
progenitor
stem
cell
mediat
protein
detect
neuron
glial
cell
brain
fetus
mother
infect
pregnanc
intern
attent
focus
zikv
rate
microcephali
report
brazil
repres
eight
increas
condit
prior
year
investig
quickli
center
zikv
base
report
regard
mother
experienc
symptom
zikv
infect
pregnanc
bolster
recoveri
zika
rna
amniot
fluid
andor
tissu
fetus
babi
diagnos
microcephali
subsequ
investig
mice
nhp
model
confirm
zikv
teratogen
sever
impact
fetal
develop
surveil
reveal
zikv
infect
also
lead
retin
ophthalmolog
abnorm
hear
loss
arthrogryposi
cerebr
ocular
calcif
overal
risk
microcephali
babi
born
mother
infect
zikv
pregnanc
rang
studi
part
us
registri
women
infect
zikv
endem
region
return
us
regardless
matern
symptomatolog
studi
brazilian
women
present
symptomat
zikv
infect
studi
rate
microcephali
birth
defect
highest
infect
occur
earli
pregnanc
studi
mice
highlight
potenti
zikv
caus
male
infertil
infect
occur
among
young
anim
immunesuppress
mice
infect
either
seven
week
age
demonstr
damag
seminifer
tubul
testicular
atrophi
oligospermia
reduc
rate
fertil
date
document
effect
zikv
infect
male
fertil
human
multipl
studi
report
evid
zikv
human
semin
fluid
andor
infect
sexual
partner
return
zikaendem
region
includ
one
case
male
male
transmiss
prolong
detect
zikv
rna
semen
least
week
note
three
studi
one
also
report
recoveri
infecti
viru
semen
eight
week
postinfect
result
support
need
evalu
surveil
zika
effect
fertil
seen
flavivirus
zikv
infect
induc
polyclon
antibodi
respons
protect
infect
diseas
correl
close
passiv
transfer
neutral
well
non
neutral
antibodi
protect
challeng
small
anim
model
structur
similar
flavivirus
lead
high
degre
crossreact
antiflaviviru
antibodi
respons
limit
amount
crossneutr
observ
antibodi
target
e
prm
detect
zikv
infect
antibodi
target
e
exhibit
signific
neutral
activ
antibodi
larg
zikv
specif
unless
infect
secondari
infect
anoth
flaviviru
case
crossreact
seen
howev
antizikv
mab
isol
shown
effect
diagnost
tool
zikv
infect
far
potent
induc
protect
antibodi
e
protein
respons
map
linear
epitop
three
e
protein
domain
well
quaternari
epitop
form
matur
structur
domain
iiitarget
antibodi
typic
possess
high
flaviviru
typespecif
bind
neutral
activ
although
cross
react
neutral
close
relat
flavivirus
contrast
antibodi
specif
epitop
e
domain
ii
broadli
crossreact
flavivirus
poorli
neutral
like
due
rel
inaccess
matur
virion
fig
limit
studi
antibodi
region
transfer
protect
model
system
antibodi
target
fusion
loop
epitop
fle
two
quaternari
epitop
present
dimer
e
protein
structur
term
envelop
dimer
epitop
ede
highli
crossreact
denv
zikv
latter
possess
signific
neutral
activ
report
zikv
infect
like
induc
antibodi
respons
prm
protein
base
studi
antiprm
antibodi
induc
denv
like
crossreact
flavivirus
sequenc
structur
similar
flaviviru
e
protein
lead
high
degre
crossreact
flaviviru
antibodi
respons
prompt
investig
prior
flaviviru
exposur
influenc
develop
antizikv
respons
effect
prior
denv
exposur
neutral
capac
antizikv
antibodi
human
still
unclear
investig
late
month
post
infect
convalesc
sera
patient
infect
denv
found
zikv
crossreact
antibodi
durabl
prior
denv
exposur
affect
develop
antibodi
respons
zikv
infect
one
concern
flaviviru
crossreact
antibodi
whether
may
enhanc
infect
observ
clinic
denv
phenomenon
term
antibodydepend
enhanc
ade
infect
hypothes
occur
antibodi
respons
primari
infect
strain
fail
neutral
infect
second
strain
bind
mark
virus
opson
fcg
receptorexpress
cell
subsequ
get
infect
import
note
ade
activ
observ
zikv
field
date
mous
certain
highli
engin
mous
model
abil
drive
ade
protect
requir
investig
studi
examin
mab
earli
convalesc
sera
denv
wnv
infect
patient
crossreact
zikv
found
neutral
zikv
infect
vitro
protect
zikvchalleng
mice
model
howev
studi
found
similar
ident
nonneutr
antibodi
well
low
level
neutral
antibodi
mediat
zikv
ade
vitro
importantli
least
two
studi
rhesu
macaqu
found
prior
denv
infect
effect
antizikv
immun
enhanc
zikv
diseas
importantli
studi
acut
zikv
infect
human
previous
infect
denv
found
clinic
evid
ade
studi
warrant
studi
clearli
warrant
howev
date
clinic
report
ade
zika
dengu
zika
viru
infect
like
induc
specif
crossreact
cellular
respons
respons
contribut
protect
infect
aid
recoveri
unclear
work
cellular
respons
zikv
reli
mous
model
infect
applic
find
human
yet
clear
infect
wild
type
immunocompet
mice
induc
polar
cell
activ
effector
phenotyp
cell
mani
cell
respond
epitop
e
protein
shresta
et
al
found
mice
lack
cell
higher
mortal
follow
zikv
infect
cell
zikvinfect
mice
recogn
epitop
prm
e
group
also
use
human
leukocyt
antigen
hla
transgen
mice
identifi
hlab
hlaa
restrict
epitop
may
relev
human
cellular
respons
zikv
cellular
respons
least
five
hlab
epitop
found
offer
protect
denv
infect
grifoni
et
al
found
denvspecif
cell
respons
induc
natur
infect
vaccin
could
also
recogn
zikvderiv
peptid
contribut
rapid
robust
antizikv
cellular
respons
denvexperienc
individu
zikv
infect
memori
cell
zikvinfect
patient
target
e
protein
found
poorli
crossreact
donor
preexpos
denv
innat
immun
system
also
affect
zikv
infect
type
iii
interferon
ifn
shown
act
autocrin
paracrin
manner
protect
trophoblast
nontrophoblast
cell
zikv
infect
may
also
help
protect
fullterm
placenta
zikv
infect
zika
viru
infect
skin
cell
human
embryon
stem
cellderiv
cerebr
organoid
found
upregul
tolllikereceptor
inhibit
could
reduc
zikvinduc
phenotyp
chang
fact
vaccin
develop
clinic
use
flavivirus
includ
yfv
jev
denv
provid
optim
vaccin
protect
zikv
infect
possibl
yfv
vaccin
liveattenu
vaccin
develop
sever
hundr
passag
asibi
yfv
strain
mous
embryo
tissu
cultur
chicken
embryo
tissu
cultur
also
without
nerv
tissu
result
attenu
strain
use
human
sinc
success
rate
four
type
inactiv
liveattenu
jev
vaccin
develop
use
global
inactiv
vero
cell
culturederiv
jev
licens
use
unit
state
vaccin
serv
paradigm
develop
zikv
vaccin
experi
licens
denv
vaccin
howev
provid
cautionari
lesson
develop
zikv
vaccin
dengvaxia
liveattenu
vaccin
consist
four
chimer
yfv
vaccin
contain
substitut
prm
e
gene
one
four
denv
strain
analysi
data
phase
iii
studi
dengvaxia
note
increas
incid
sever
denv
infect
among
young
children
result
vaccin
licens
use
individu
greater
age
year
recent
analysi
compani
found
regardless
age
vaccin
individu
associ
signific
risk
sever
denv
infect
increas
sever
denv
infect
attribut
ade
prospect
studi
larg
thai
cohort
find
correl
vitro
ade
clinic
sever
secondari
case
denv
moreov
recent
studi
found
evid
sever
zika
viru
infect
occur
pregnanc
relat
denv
sero
statu
write
differ
nucleic
acid
vaccin
dna
plasmid
mrna
inactiv
viru
vaccin
measl
vector
vaccin
target
zika
viru
advanc
clinic
trial
tabl
dna
vaccin
platform
use
twentyf
year
creat
candid
vaccin
numer
pathogen
dna
vaccin
creat
clone
antigen
pathogen
dna
plasmid
vaccin
administ
either
muscl
skin
resid
cell
take
vaccin
produc
encod
antigen
present
immun
system
dna
vaccin
platform
reliabl
induc
cellular
humor
immun
carri
virtual
risk
caus
diseas
sinc
deliv
small
portion
full
pathogen
genom
addit
dna
vaccin
design
manufactur
distribut
faster
cheaper
virusor
proteinbas
vaccin
group
extens
experi
design
improv
vaccin
cassett
synthet
dna
vaccin
pathogen
knowhow
rapidli
move
vaccin
candid
clinic
past
five
year
develop
synthet
dna
vaccin
candid
target
ebola
viru
middl
east
respiratori
syndrom
coronaviru
merscov
respons
outbreak
viru
vaccin
encod
synthet
consensu
viral
surfac
protein
antigen
either
ebola
viru
glycoprotein
gp
spike
protein
merscov
induc
immun
divers
strain
viru
vaccin
administ
use
electropor
ep
enhanc
intramuscular
im
deliveri
use
ep
ebola
viru
vaccin
also
administ
novel
epenhanc
intraderm
id
deliveri
platform
simpler
toler
im
deliveri
ebola
viru
vaccin
advanc
anim
studi
clinic
less
month
merscov
reach
clinic
month
preclin
studi
show
vaccin
protect
nhp
infect
diseas
immunogen
number
speci
includ
camel
background
thought
rapid
approach
develop
deploy
zikv
vaccin
reason
declar
public
health
emerg
start
effort
extens
research
pathogenesi
immunogen
relat
flavivirus
dengu
west
nile
viru
littlepublish
literatur
zikv
addit
avail
reagent
establish
assay
investig
zikv
lack
resourc
provid
uniqu
development
challeng
abl
leverag
experi
creat
synthet
dna
vaccin
pathogen
produc
zikv
vaccin
get
clinic
within
seven
month
fig
design
synthes
multipl
zikv
dna
vaccin
evalu
mice
abil
induc
zikvspecif
immun
respons
vaccin
administ
epenhanc
im
inject
use
ep
among
candid
test
vaccin
encod
consensu
sequenc
zikv
structur
gene
well
vaccin
encod
structur
gene
sequenc
brazilian
zikv
strain
zikv
strain
origin
africa
vaccin
candid
test
immunogen
final
vaccin
downselect
due
consist
abil
induc
strong
zikvspecif
humor
cellular
immun
multipl
haplotyp
mous
immunogen
studi
vaccin
contain
synthet
zikv
prme
consensu
sequenc
antigen
creat
align
prm
e
sequenc
multipl
zikv
isol
collect
determin
consensu
nucleotid
posit
consensu
antigen
account
genet
chang
appear
time
pathogen
potenti
make
adept
induc
crossreact
immun
respons
multipl
divers
strain
pathogen
evalu
immunocompet
mice
induc
full
seroconvers
two
immun
third
dose
vaccin
gener
highest
antibodi
level
maintain
least
one
month
follow
final
immun
addit
bind
recombin
zikv
prme
antigen
elisa
antibodi
induc
could
also
bind
zikv
prme
produc
infect
cell
western
blot
indirect
immunofluoresc
analys
importantli
antibodi
respons
could
neutral
zikv
infect
vitro
high
titer
mice
receiv
three
dose
vaccin
also
gener
modest
cellular
respons
zikv
includ
polyfunct
cell
next
step
preclin
develop
requir
model
system
evalu
whether
immun
respons
gener
mice
abl
protect
anim
zikv
infect
andor
diseas
previou
research
dengu
west
nile
virus
indic
immunocompet
mice
develop
diseas
follow
infect
mice
lack
function
innat
immun
system
could
support
flaviviru
replic
suffer
diseas
base
result
set
collabor
develop
zikv
challeng
model
mice
lack
interferon
ab
receptor
ifnar
inabl
respond
type
interferon
allow
robust
viral
replic
found
infect
mice
zikv
differ
rout
includ
intraven
subcutan
intraperiton
intracrani
inject
result
vivo
viral
replic
caus
mice
develop
diseas
could
lead
death
high
viral
challeng
dose
use
sign
diseas
zikv
infect
mice
includ
weight
loss
decreas
mobil
andor
temporari
paralysi
postmortem
examin
infect
mice
reveal
zikvinduc
neurolog
effect
detect
histolog
subsequ
character
model
collabor
led
one
first
report
zikvinduc
damag
reproduct
system
fertil
male
mice
clearli
observ
effect
zikv
infect
mice
made
ideal
model
evalu
protect
efficaci
cohort
mice
receiv
three
immun
cohort
receiv
singl
immun
fulli
protect
morbid
mortal
follow
zikvchalleng
compar
shamvaccin
cohort
prove
critic
mileston
develop
vaccin
also
lower
viral
load
blood
semen
tissu
protect
male
mice
zikvinduc
testicular
damag
combin
data
immun
compet
mice
test
model
establish
immun
could
protect
zikvmedi
diseas
also
suggest
may
also
prevent
transmiss
viru
lower
viral
load
preclin
test
conduct
newli
develop
zikvchalleng
model
rhesu
macaqu
anim
develop
clinic
diseas
follow
zikv
challeng
support
viral
replic
monitor
perform
rtpcr
blood
tissu
immun
rhesu
monkey
epenhanc
id
inject
induc
modest
cellular
respons
two
dose
robust
antibodi
respons
monkey
receiv
fulli
seroconvert
second
immun
antibodi
respons
abl
neutral
zikvinfect
vitro
assay
high
titer
passiv
transfer
immun
monkey
sera
mice
prior
zikv
challeng
protect
morbid
mortal
suggest
antibodi
respons
induc
main
driver
protect
importantli
monkey
vaccin
significantli
reduc
viral
load
blood
follow
zikv
challeng
compar
shamvaccin
anim
base
encourag
preclin
data
anim
model
fda
approv
clinic
test
june
nearli
seven
month
initi
vaccin
designsynthesi
worldwid
warn
zikv
interim
result
week
phase
clinic
trial
report
flaviviru
volunt
trial
receiv
three
dose
either
mg
mg
intraderm
inject
follow
well
toler
without
report
seriou
advers
event
sae
major
subject
dose
group
bind
antibodi
titer
zikvprm
two
immun
subject
respons
three
immun
major
subject
group
signific
vitro
neutral
antibodi
titer
zikv
third
inject
antibodi
respons
major
patient
group
block
zikv
infect
glioblastoma
cell
line
protect
capac
human
immun
respons
investig
passiv
transfer
serum
immun
subject
mice
prior
lethal
zikv
challeng
result
studi
show
sera
collect
third
immun
protect
mice
morbid
mortal
follow
zikv
challeng
protect
efficaci
serum
transfer
correl
measur
vitro
neutral
titer
suggest
antibodi
may
engag
altern
effector
mechan
block
diseas
data
consist
report
vaccin
flavivirus
suggest
reevalu
protect
criteria
flaviviru
vaccin
import
followon
studi
current
assess
part
doubleblind
placebocontrol
studi
puerto
rico
zikv
endem
region
rapid
develop
timelin
highlight
potenti
dna
vaccin
platform
meet
challeng
develop
therapi
treat
andor
stop
spread
emerg
infecti
diseas
past
two
year
learn
pathogenesi
zikv
previou
year
sinc
discoveri
believ
caus
mild
selflimit
ill
zikv
known
teratogen
signific
risk
factor
develop
guillainbarr
syndrom
import
ongo
research
tri
elucid
etiolog
extent
zikvmedi
birth
defect
risk
factor
lead
although
evid
zikv
infect
affect
sperm
develop
fertil
human
male
dramat
effect
zikv
genitalia
male
mice
along
fact
zikv
rna
detect
sperm
month
infect
suggest
studi
evalu
phenomenon
warrant
also
necessari
understand
sexual
transmiss
zikv
contribut
zikvmedi
congenit
abnorm
along
rapid
acquisit
knowledg
biolog
zikv
infect
rapid
concert
effort
develop
immunotherapi
vaccin
mab
therapeut
prevent
andor
treat
zikv
infect
within
seven
month
initi
vaccin
designsynthesi
four
month
declar
zikv
world
health
emerg
collabor
group
led
gene
one
life
scienc
inovio
pharmaceut
vaccin
candid
approv
clinic
test
initi
result
suggest
candid
safe
immunogen
addit
candid
use
differ
vaccin
platform
also
develop
evalu
clinic
zikvtarget
mab
may
anoth
import
weapon
combat
infect
diseas
especi
peopl
good
candid
vaccin
pregnant
women
although
mab
shown
protect
efficaci
anim
model
much
work
remain
done
advanc
therapeut
clinic
evalu
protect
dose
assur
mediat
ade
zikv
denv
flavivirus
much
work
remain
rapid
effort
scientist
world
health
agenc
understand
zikvinfect
develop
treatment
option
provid
blueprint
respond
emerg
infecti
diseas
threat
jjk
mj
jnm
employe
geneon
life
scienc
inc
ccr
sw
jjk
employe
inovio
pharmaceut
follow
report
start
plasmid
design
vitro
test
februari
time
declar
zika
public
health
emerg
intern
concern
complet
first
mous
studi
begun
nhp
immunogen
studi
may
first
nhp
studi
complet
ind
file
shortli
phase
clinic
trial
start
june
short
month
initi
vaccin
design
start
preclin
work
sinc
publish
septemb
june
preliminari
report
clinic
trial
data
publish
octob
receiv
salari
benefit
includ
ownership
stock
stock
option
km
disclos
grant
fund
industri
collabor
speak
honoraria
fee
consult
receiv
consult
fee
inovio
pharmaceut
relat
dna
vaccin
develop
patent
applic
dna
vaccin
develop
deliveri
dna
encod
monoclon
antibodi
pend
inovio
pharmaceut
remuner
includ
direct
payment
dbw
disclos
grant
fund
sab
board
servic
industri
collabor
speak
honoraria
fee
consult
servic
includ
serv
scientif
review
committe
advisori
board
remuner
includ
direct
payment
andor
stock
stock
option
note
potenti
conflict
associ
work
pfizer
bristol
myer
squibb
inovio
pharmaceut
merck
vgxi
geneo
astrazeneca
potenti
other
licens
technolog
laboratori
creat
job
biotechpharma
industri
author
declar
compet
financi
interest
